Dexcom Inc
NASDAQ:DXCM
Dexcom Inc
NASDAQ:DXCM
Price:
127.2 USD
-0.15%
Market Closed
Updated:
May 1, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
61
Current
80.8
Median
12.5
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=61
Enterprise Value
/
48.8B
EBITDA
800.3m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49B USD | 61 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
185B USD | 19.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
132.2B USD | 54.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.9B USD | 24.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
108B USD | 13.7 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
105.6B USD | 31.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.6B USD | 18.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.1B EUR | 18.4 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.4B CNY | 28.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.7B USD | 26.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
38.9B USD | 32.4 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
39.3
2-Years Forward
EV/EBITDA
31.3
3-Years Forward
EV/EBITDA
25.4
You don't have any saved screeners yet
